DubaiRadiotheranosticsSummitHow to establish radioligand therapy for advanced cancer care in your region?
How to establish radioligand therapy for advanced cancer care in your region?
29 January 2025
Register now (SOLD OUT)Radiotheranostics, radiopharmaceuticals with antitumour effects, have seen rapid development over the past decade. The Dubai Radiotheranostics Summit aims to raise awareness, as well as address challenges and opportunities around this cancer care approach. By gathering multiple points of view from specialists from the field, we aim to give a broad perspective of how to accelerate the setting-up of the structure to enhance patient access.
Concept
& Landscape
Infrastructure
& Technology
Clinical:
Experience with Radioligand Therapy
Patient TestImonials
& Case StudIES
Sponsors & Partners
Program
Rebecca Lo bue
CEO of the Oncidium Foundation
Dr. Batool Albalooshi
MD, Facharzt, FEANM, Head and consultant at Dubai Nuclear Medicine & Molecular Imaging Center-Dubai Health
H.E. Mr. Antoine DELCOURT
Ambassador of the Kingdom of Belgium to the United Arab Emirates
What are Radiotheranostics
Products on the global market and what's next
Landscape local x global - Barriers/challenges
Dr. Munir Ghesani
Past President of SNMMI, Chief Medical Officer at United Theranostics
Testimonial of a person treated with 177Lu-PSMA and one with 177Lu-DOTATATE
Case-study: Regional Experience with PSMA RLT in Prostate Cancer
Case-study: NET treatment
Clinical and Regulatory Aspects of Radio-ligand Therapy: Trends, Guidelines and Future Aspirations
Q&A
Dr. Akram Al-Ibraheem
Chairman of Nuclear Medicine Department, King Hussein Cancer Center (KHCC)
Dr. Munir Ghesani
Past President of SNMMI, Chief Medical Officer at United Theranostics
Dr. Ilya Gipp, MD, PhD
Oncology Chief Medical Officer at GE HealthCare
International Atomic Energy Agency (IAEA) support to build radiopharmaceutical capacity
Dr. Valery Radchenko
Consultant at International Atomic Energy Agency (IAEA)
Theranostics and Role of Arab Society of Nuclear Medicine in the region
Dr. Batool Albalooshi
MD, Facharzt, FEANM, Head and consultant at Dubai Nuclear Medicine & Molecular Imaging Center-Dubai Health
HCS readiness and challenges for radioligand therapy
Radjaa Medhi, PhD
RLT Export & Growth Market Head
Q&A session
All
How to set-up a nuclear medicine center - Infrastructure: Hospital, radiopharmacy and cyclotron site.
Dr. Dmitry Cherkasov
MD.,MBA, Theranostics Association VP, HASCCA founder; Doctorant - co-founder
How to set-up a nuclear medicine center - Business model: Project and facility management, investment and human resources.
Dr. Yehia Omar
Director of PET/CT and Theranostics unit at Misr Radiology Center
The way to radiotheranostic: Institut Jules Bordet’s evolution to a center of excellence
Dr. Zena Wimana
Director of the Radiopharmacy - Hôpital Universitaire de Bruxelles (H.U.B)
Round table
Round table with representative from world suppliers
Ms. Ece Süreyya Dagdele - ITM
Mr. Mohammed Tahlak - Radsa Physics
Dr. Ilya Gipp - GE HealthCare
Mr. Amer Salha - Monrol UAE
Radjaa Medhi, PhD - Novartis
Rebecca Lo bue
CEO of the Oncidium Foundation
Scientific Board
DR. Alice Viana
Scientific Director at Oncidium foundation
Belgium
Dr. Batool Albalooshi
MD, Facharzt, FEANM, Head and consultant at Dubai Nuclear Medicine & Molecular Imaging Center-Dubai Health
United Arab Emirates
Dr. Aruna Korde
Technical Officer at International Atomic Energy Agency (IAEA)
Austria
DR. Dmitry Cherkasov
MD.,MBA, Theranostics Association VP, HASCCA founder; Doctorant - co-founder
Russia
Dr. Zena Wimana
Director of the Radiopharmacy - Hôpital Universitaire de Bruxelles (H.U.B)
Belgium
Dr. Cristiana Gameiro
Expert Member of the Belgian and European Pharmacopoeias; Product Manager at IBA, Ph.D., MBA- IBA Fellow
Belgium
General Information
This 1st edition of Oncidium foundation & partners’ congress empowers healthcare leaders to bring advanced radiotheranostics to their regions, offering cancer patients personalized, targeted treatment that improves outcomes and enhances quality of life.
Focused on Middle East, Africa and Asia, with a program developed for investors, head of hospitals, oncologists, policymakers, cross-niche specialists, and healthcare industry representatives, to bring radiotheranostics to the their regions.
VENUE
Millennium Plaza Downtown
23215 Sheikh Zayed Rd
(15min from Arab Health)
The Oncidium foundation
The Oncidium Foundation is a dedicated nonprofit organization committed to advancing nuclear medicine therapies for cancer care worldwide. Our primary mission revolves around education, awareness, and support for individuals facing the daily battle against cancer, with a focus on those in need of access to the best possible care.
Through our initiatives and the groundbreaking RLT-Connect platform, we aim to bridge these gaps and provide financial support to patients in underserved regions, ensuring they receive the best possible cancer care. Our dedication to this cause drives us to continue raising awareness, educating, and advocating for equitable access to cutting-edge treatments that offer hope and a chance at longer, better lives for cancer patients worldwide.
Contact us
VENUE
Millennium Plaza Downtown
23215 Sheikh Zayed Rd - Trade Centre
Trade Centre 1 - Dubai - United Arab Emirates
Headquarters
The Oncidium foundation
Rue Emile Francqui 6, boite 5
1435 Mont-Saint-Guibert – Belgium